Next 10 |
2024-03-21 07:55:00 ET DENVER, Colo., Mar 21, 2024 ( 247marketnews.com )- Bionomics Limited (NASDAQ: BNOX ) released, this morning, the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder. The full data analysis shows that ATTUNE ...
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continu...
ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous ...
2024-02-04 11:01:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Small-cap stocks are particularly vulnerable to higher interest rates. So it’s not surprising that many of these stocks are struggling in a higher-for-longer rate environment. But the wh...
2024-01-22 08:26:07 ET Losers: Archer Daniels Midland Co. ADM -15% on leave amid accounting probe, trims FY 2023 earnings guidance . B. Riley Financial ( RILY ) -15% issues financial Statement . Bionomics Ltd. ( BNOX ) -11% provides a Review of 20...
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration (FDA) anticipated in Q2’24. Positive End of Phase 2b (EoP2...
ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous ...
2023-12-06 08:47:19 ET More on Bionomics HC Wainwright ups Bionomics to buy, cites positive data for PTSD drug Bionomics stock rockets 415% on positive study for PTSD drug Seeking Alpha’s Quant Rating on Bionomics Historical earnings data for Bionomics...
A psychometric analysis concluded that Subjective Units of Distress Scale (SUDS) is a psychometrically valid, sensitive, and reliable tool for evaluation of social anxiety. SUDS will be used as the primary outcome in future Phase 3 social anxiety disorder (SAD) clinical trials. ...
2023-11-13 10:00:16 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stocks to watch in the Health Care sector a...
News, Short Squeeze, Breakout and More Instantly...
Bionomics Limited Company Name:
BNOX Stock Symbol:
NASDAQ Market:
Thursday, Bionomics Limited (NASDAQ:BNOX) released a full dataset analysis from its Phase 2b ATTUNE trial of BNC210 in patients with post...
2024-03-21 07:55:00 ET DENVER, Colo., Mar 21, 2024 ( 247marketnews.com )- Bionomics Limited (NASDAQ: BNOX ) released, this morning, the full dataset analysis from its Phase 2b ATTUNE trial in patients with post-traumatic stress disorder. The full data analysis shows that ATTUNE ...
BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210’s emerging safety and tolerability profile continu...